Bernese medtech start-up machineMD has advanced to the second phase of the prestigious DayOne Health 4.0 Accelerator, making it one of the top five finalists from an initial pool of 15.
machineMD, a spin-off from the University Hospital of Bern now located at the Sitem Startup Club, stands out for its innovative approach to neurological disorder diagnosis. The company’s groundbreaking device, neos®, leverages virtual reality technology to conduct standardized and automated neuro-ophthalmic examinations, enhancing the precision and speed of diagnosing conditions like brain tumors and multiple sclerosis.
The first phase of the 2023 DayOne Health 4.0 Accelerator, which ran from September to November, saw machineMD among four Swiss start-ups selected from 109 applications spanning 35 countries. The second phase focuses on further nurturing the finalists, preparing them for potential collaborations and partnerships, particularly with biopharma companies.
The program identifies key areas such as optimizing patient identification in clinical trials, enhancing clinical development with data and clinical tools, streamlining clinical operations, and improving patient experiences to boost outcomes.
As machineMD moves into the second phase, it will benefit from continued mentorship, expert exchanges, and introductions to vital healthcare ecosystem players. The support aims to prime the start-ups for collaborations at the pharma interface.
Founded in 2019 by Prof. Mathias Abegg, MD, PhD, and a team of entrepreneurs and medical device experts, machineMD has already made significant strides. Its flagship device, neos®, is recognized as a Class I medical device in Switzerland and the UK, with plans to introduce it as a Class II(a) device in the USA. With its advanced technology and the backing of the DayOne Health 4.0 Accelerator, machineMD is well-positioned to expand its impact in the field of medtech and beyond.
